Source 1primary paper2025MED
Toolkit/HER2-targeting CAR-M
HER2-targeting CAR-M
Also known as: CAR-M, HER2-targeting CAR-macrophage
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Usefulness & Problems
Why this is useful
This is a HER2-directed CAR-macrophage generated using the reported delivery platform. In the abstract, it functions as an engineered macrophage with specific phagocytic activity against HER2-expressing tumor cells.; antigen-specific macrophage engineering; in vitro phagocytic targeting of HER2-expressing tumor cells
Source:
This is a HER2-directed CAR-macrophage generated using the reported delivery platform. In the abstract, it functions as an engineered macrophage with specific phagocytic activity against HER2-expressing tumor cells.
Source:
antigen-specific macrophage engineering
Source:
in vitro phagocytic targeting of HER2-expressing tumor cells
Problem solved
It provides a way to create antigen-directed macrophages for tumor-cell phagocytosis. In this paper, it serves as the functional output enabled by improved macrophage transfection.; enables functional CAR-macrophage generation using non-viral mRNA delivery
Source:
It provides a way to create antigen-directed macrophages for tumor-cell phagocytosis. In this paper, it serves as the functional output enabled by improved macrophage transfection.
Source:
enables functional CAR-macrophage generation using non-viral mRNA delivery
Problem links
enables functional CAR-macrophage generation using non-viral mRNA delivery
LiteratureIt provides a way to create antigen-directed macrophages for tumor-cell phagocytosis. In this paper, it serves as the functional output enabled by improved macrophage transfection.
Source:
It provides a way to create antigen-directed macrophages for tumor-cell phagocytosis. In this paper, it serves as the functional output enabled by improved macrophage transfection.
Published Workflows
Objective: Develop a bioactive lipid nanoparticle that improves mRNA delivery into primary macrophages and use it to generate functional HER2-targeting CAR-macrophages.
Why it works: The paper hypothesizes that embedding a cellular modulator within the LNP structure can synergistically overcome biological barriers in primary macrophages that are not solved by physicochemical optimization alone.
transient modulation of target cell state by the nanocarrierintegration of arachidonic acid as a functional structural componentLNP design and synthesisformulation optimizationmRNA deliveryin vitro functional phagocytosis testing
Stages
- 1.ARA-LNP design and synthesis(library_build)
To instantiate the proposed bioactive nanocarrier paradigm before optimization and testing.
Selection: Create a novel LNP incorporating arachidonic acid as a functional structural component.
- 2.Formulation optimization in primary macrophages(broad_screen)
To identify a formulation that overcomes macrophage transfection barriers before applying the platform to CAR-M generation.
Selection: Optimize ARA content and mRNA payload for transfection efficiency in primary M2-polarized BMDMs.
- 3.Functional CAR-macrophage validation(confirmatory_validation)
To confirm that improved delivery translates into a therapeutically relevant macrophage engineering outcome.
Selection: Use the optimized delivery platform to generate HER2-targeting CAR-M and test phagocytic function against HER2-expressing tumor cells.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen-specific phagocytosismrna-mediated transient gene expressionnanocarrier-mediated cellular state modulation to enhance gene deliveryTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
Its generation requires macrophage engineering with a HER2-targeting CAR mRNA or construct and a compatible delivery platform. The reported validation also requires HER2-expressing tumor cells for in vitro testing.; requires efficient mRNA delivery into primary macrophages; depends on HER2-expressing target tumor cells for the reported functional assay
The abstract does not establish in vivo efficacy, persistence, or safety. It also does not compare this construct to other CAR-M designs or delivery methods.; abstract does not specify CAR design details; evidence is limited to in vitro activity
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successPrimary Cellsapplication demo
in vitro phagocytosis assay
Inferred from claim c3 during normalization. Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro. Derived from claim c3. Quoted text: Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Source:
Supporting Sources
Ranked Claims
Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Incorporating a cellular modulator directly into LNP structure is proposed to synergistically overcome intrinsic biological barriers to gene delivery in primary macrophages.
Here, we introduced a "bioactive nanocarrier" paradigm, hypothesizing that incorporating a cellular modulator directly into LNP structure can synergistically overcome these barriers.
The study presents a design principle in which the nanocarrier transiently modulates target cell state to enhance gene delivery for macrophages and other hard-to-transfect immune cells.
This work presents a powerful strategy where the nanocarrier itself transiently modulates the target cell state to enhance gene delivery, providing a new design principle for engineering macrophages and other hard-to-transfect immune cells for therapeutic applications.
An optimized ARA-LNP formulation achieved 83.76% transfection efficiency in primary M2-polarized bone marrow-derived macrophages.
Systematic optimization of the ARA content and mRNA payload revealed a formulation that achieves high transfection efficiency (83.76%) in primary M2-polarized bone marrow-derived macrophages (BMDMs)
transfection efficiency 83.76 %
Approval Evidence
1 source1 linked approval claimfirst-pass slug her2-targeting-car-m
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Source:
applicationsupports
Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Source:
Comparisons
Source-stated alternatives
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Source:
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Source-backed strengths
demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro
Source:
demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro
Compared with CAR-engineered macrophages
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Relative tradeoffs: abstract does not specify CAR design details; evidence is limited to in vitro activity.
Source:
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Compared with CAR-macrophages
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Relative tradeoffs: abstract does not specify CAR design details; evidence is limited to in vitro activity.
Source:
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Compared with chimeric antigen receptor macrophage
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Relative tradeoffs: abstract does not specify CAR design details; evidence is limited to in vitro activity.
Source:
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Compared with chimeric antigen receptor macrophages
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Relative tradeoffs: abstract does not specify CAR design details; evidence is limited to in vitro activity.
Source:
The abstract discusses CAR-M therapy broadly but does not name alternative CAR-M constructs. It implicitly contrasts successful CAR-M generation here with the general difficulty of engineering primary macrophages.
Ranked Citations
- 1.